Aldose reductase inhibition: studies with alrestatin

Area of Science:

• Biomedical Science
• Pharmacology
• Neurology

Background:

• The sorbitol pathway is implicated in diabetic peripheral neuropathy pathogenesis.
• Aldose reductase inhibitors, like alrestatin, are potential therapeutic agents.

Purpose of the Study:

• To evaluate the safety and efficacy of alrestatin in diabetic peripheral neuropathy.
• To investigate the role of the sorbitol pathway in diabetic neuropathy.

Main Methods:

• Alrestatin administered intravenously and orally to diabetic patients and normal subjects.
• Assessed acute toxicity, serum half-life, and urinary recovery.
• Monitored subjective clinical symptoms, objective neurological examinations, and nerve conduction velocities.

Main Results:

• Alrestatin demonstrated no acute toxicity and had a short serum half-life.
• Intravenous alrestatin led to temporary subjective symptom improvement in two patients, but no objective changes.
• Oral alrestatin showed no subjective or objective improvements in a 30-day trial.

Conclusions:

• Alrestatin may not be effective in advanced diabetic peripheral neuropathy.
• Higher peak serum levels might be necessary for therapeutic effect.
• Further research in early-stage diabetic neuropathy is warranted to test the sorbitol pathway hypothesis.